North of a billion biotech VC dollars to come from C-Bridge, Rothschild as global biopharma capital flows
Two powerhouse private equity firms, based out of Europe and China respectively, are looking at multi-million funds to fuel their global biopharma pursuits.
France’s Edmond de Rothschild Investment Partners has raised $430 million (€345 million) for BioDiscovery 5 — 80% larger than the fourth life sciences fund it closed in 2012. Meanwhile, six months after closing a $400 million biopharma fund, PEI reports that Chinese private equity player C-Bridge Capital is raising a $650 million third fund.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
